BDR Pharmaceuticals launches anti-Cancer drug for advanced Gastric Cancer
BDR Pharmaceuticals announced the first generic launch in India – Furmecil which was an oral medicine for the treatment of advanced gastric cancer on Wednesday. According to the Major Pharmacy, anti-cancer drugs have shown high effectiveness with profitable safety profiles.
Oral medicine, known as S-1, is a combination of three drugs – tegafur, Gimeracil, and Oteracil will soon be available on the Indian market. I will be sold in capsules in two strengths (15 mg + gimeracil 4.35 mg + oteracil 11.80 mg & 20 mg + gimeracil 5.80 mg + oteracil 15.80 mg).
Our vision is to bring drugs available globally and very effectively for Indian patients who make them accessible at affordable prices, BDR Pharma, lead to bring cost-effective treatment for gastric cancer in India as part of its newest pharmaceutical innovation. Launch Our focus of the first molecule that has just advanced in the treatment of various indications of cancer is a testimony for our strong commitment to provide access to affordable drugs for Indian cancer patients with high-quality standards without sacrificing patient safety, “Raheel Shah, Director of Business Development On behalf of BDR Pharmaceuticals, Mumbai said during the launch.
Gastric cancer is one of the most important malignancies in terms of cases and mortality throughout the world. This is the fourth most common malignant disease and the second main cause of cancer-related deaths throughout the world.At present, care includes targeted molecules, a combination of local operations and radiation therapy and systemic chemotherapy. According to Indian journals about medical and pediatric oncology, combination therapy with the S-1 has been going on to obtain a better survival rate for patients, lower costs and better quality of life.
